Cost, Economics and Databases of Pharmaceutical Drugs in Public Health: Second Edition

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Medication Management".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1257

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, 61-701 Poznań, Poland
Interests: pharmacology; pharmacoeconomics; medical and drug databases; quality of life; EBM; RWE; therapy costs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Public health does not only concern patients and medical procedures aimed at improving the health of the population, subpopulations, and target groups in terms of treating disease. Rather, it includes issues such as the quality of life, the costs of procedures, disease prevention, and drugs. These issues are critical elements of national, continental and global healthcare strategies, as perfectly demonstrated by the COVID-19 pandemic.

Pharmacoeconomics, health economics, and medical decision economics are just some of the essential elements of medical strategy, which is perceived differently in different countries.

This Special Issue, entitled “Cost, Economics and Databases of Pharmaceutical Drugs in Public Health: Second Edition”, offers a unique opportunity to show the multifaceted nature of this issue, starting from costs and ending with the use of medical databases and systematic reviews in the effective use or allocation of resources to treat patients (including drugs).

I cordially invite you and your staff to submit publications to this Special Issue.

Dr. Krzysztof Kus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Insecurity
  • Food
  • Cosmetics
  • Health
  • Healthcare
  • Medical device
  • Dietary supplements
  • Policies
  • Assessment
  • Databases
  • Quality of life
  • Real World Evidence (RWE)
  • Evidence-Based Medicine (EBM)
  • Pharmacy Evidence-Based (PEB)
  • Therapy cost
  • Economics
  • Pharmacoeconomics
  • Health economics
  • Budget Impact Analyses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

25 pages, 558 KiB  
Systematic Review
Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review
by Nam Xuan Vo, Huong Lai Pham, Uyen My Bui, Han Tue Ho and Tien Thuy Bui
Healthcare 2024, 12(19), 1950; https://doi.org/10.3390/healthcare12191950 - 29 Sep 2024
Viewed by 888
Abstract
Objectives: Pneumococcal disease, caused by Streptococcus pneumoniae, is the leading cause of mortality in children worldwide. The tremendous direct cost of hospital admissions and significant indirect costs from productivity loss contribute considerably to its economic burden, with vaccination being the only efficient [...] Read more.
Objectives: Pneumococcal disease, caused by Streptococcus pneumoniae, is the leading cause of mortality in children worldwide. The tremendous direct cost of hospital admissions and significant indirect costs from productivity loss contribute considerably to its economic burden, with vaccination being the only efficient protection against the illness. Our study aims to summarize the cost-effectiveness of the pneumococcal conjugate vaccine (PCV) implemented in the pediatric population. Methods: Employing the online databases PubMed, Embase, and Medline, we looked for economic evaluations from 2018 until March 2024. The Incremental Cost-Effectiveness Ratios (ICER) and Quality-Adjusted Life Years (QALY) were the primary outcomes for measuring the cost-effectiveness of PCVs. A 28-item CHEERS 2022 checklist was applied to assess the quality of the collected studies. Results: Of the 16 papers found, 9/16 discussed the lower-valent vaccines (PCV13, PCV10) and 7/16 examined the higher-valent vaccines (PCV20, PCV15). PCV13 and PCV10 involved greater costs and generated more QALY compared to no vaccination. Both PCV15 and PCV20 averted substantial healthcare costs and yielded greater quality of life than PCV13. Additionally, PCV20 was a dominant strategy compared to PCV15. Conclusions: Utilizing PCV13 is a very cost-effective option compared to not getting vaccinated. Transitioning from PCV13 to PCV20 would result in higher QALY gain and more cost-saving than switching to PCV15. Full article
Show Figures

Figure 1

Back to TopTop